TBCE and psoriasis: IL-17 inhibitors exert their therapeutic activity in psoriasis predominantly by interrupting IL-17-driven activation of the NF-κB cascade, thereby dampening the pro-inflammatory cytokine networks that sustain KCs hyperproliferation and chronic cutaneous inflammation.